Alpha Tau completes enrollment in pivotal ReSTART trial for recurrent skin cancer

Alpha Tau Medical Ltd

DRTS

0.00

Alpha Tau Medical completed enrollment in ReSTART, its first U.S. pivotal trial for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, positioning program to support FDA pre-market approval.
Study results have not been presented; trial now moves into follow-up to generate response and durability data.
Completion of enrollment marks shift from recruitment to evidence build for potential first U.S. commercial clearance of Alpha DaRT in this indication.
Company has already started modular PMA filing, signaling regulatory work is progressing in parallel with clinical readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080900PRIMZONEFULLFEED9716239) on May 08, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.